The relation between Programmed death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) and cardiovascular diseases

PD-1/PD-L1 on cardiovascular diseases - PD-1/PD-L1 on cardiovascular diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036618

Enrollment

5000

Registered

2019-04-27

Start date

2017-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular diseases (myocardial infarction, angina, heart failure, arrhythmia, peripheral artery disease, aortic dissection, and aneurysm)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria is all patients admitted Kumamoto University Hospital due to diagnosis or treatment for their cardiovascular diseases.

Exclusion criteria

Exclusion criteria: ACS cohort 1) Patients who do not consent for this study. 2) active malignancy 3) hemodialysis 4) active systemic inflammatory diseases (autoimmune diseases, rheumatoid diseases required immunosuppression therapies, and severe infectious diseases)

Design outcomes

Primary

Measure	Time frame
1) The assessment of serum levels of PD-1 and PD-L1 in the pathophysiological findings in patients with cardiovascular diseases. 2) The association between PD-1 and PD-L1, and cardiovascular outcomes in patients with cardiovascular diseases.	—

Countries

Japan

Contacts

Public ContactKoichiro Fujisue

Kumamoto University Department of Cardiovascular Medicine Graduate School of Medical Sciences

fujisues@kumamoto-u.ac.jp81-96-373-5175

Outcome results